Contact Us


The Mount Sinai Medical Center
234 East 85th Street 2nd Ave 5th Floor
New York, New York 10028
Tel: 212.731.3311


Schweiger Dermatology Group
1727 Broadway, 2nd Floor
New York, New York 10019
Tel: 212.489.6669


Dr. Khorasani’s Research Focus: Minimal Scar Wound Repair

Dr. Khorasani Scientist Surgeon

Dr. Khorasani is extremely interested in minimal scar wound repair and has done extensive research in this area. Unlike adult wounds, fetal wounds heal without scarring. Dr. Khorasani’s goal has been to investigate the environmental and intrinsic differences in adult vs. fetal wound repair and attempt to establish scarless wound repair in adult wounds. In particular, Dr. Khorasani has focused on the molecular agents involved in fetal scarless wound healing including the TGF family of molecules and Fibromodulin.

Clinical Trials as Principal Investigator

Skin closure device study:

  • Zipline incision approximation vs. suture study
  • A multi-site prospective randomized study designed to evaluate user preferences for the Zipline 3 system vs. conventional suturing

Laser treatment of post surgical scars:

  • Scar analysis of post surgical wounds treated with an ablative fractional CO2 laser
  • A prospective randomized study designed to evaluate the optimal treatment interval post surgery as well as the histological and genetic changes that occur in scar remodeling (IRB pending)

Botox treatment of post surgical wounds: 

  • Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring: A Double Blinded, Randomized Controlled Trial
  • A randomized trial designed to evaluate the effect of prophylactic Botulinum Toxin on forehead scars

Oncologic Trials:

  • A prospective observational study of treatment patterns and effectiveness and safety outcomes in advanced basal cell carcinoma and basal cell carcinoma nevus syndrome patients
  • In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC)
  • The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
  •  Phase Ib/2 Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects with Previously Untreated, Unresectable Stage IIIb/IV Melanoma